CYBN:CC News and Press, CYBIN INC. From 08/21/23

Cybin (NYSE American: CYBN) (NEO: CYBN) was featured in a recent interview with Proactive Investors that covers protection of the company’s IP with the granting of a second U.S. patent for its its deuterated analog programs. Cybin CEO Doug Drysdale joined Steve Darling from Proactive to...

--News Direct-- Cybin Inc CEO Doug Drysdale joined Steve Darling from Proactive to share news the US Patent and Trademark Office has granted another patent to a deuterated psilocybin analog within the company's CYB003 investigational drug program. This patent is expected to provide ex...

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has begun preparations for good manufacturing practices (“GMP”) production o...

- CYB003 capsule formulation is designed to be stable, dose flexible, patient-friendly and commercially scalable - - Shipments of CYB003 capsules to clinical sites expected in Q1 2024 - - R ecently granted U.S. patent covers composition of matter claims and treatment methods i...

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that the U.S. Patent and Trademark Office (“USPTO”...

- Newly granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041 - - Company’s intellectual property portfolio now encompasses 2 granted U.S. patents, and over 50 pending patent applications across 6 ...

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting unaudited financial results for its first quarter, the period ended June 30, ...

- Topline clinical data readouts expected in Q3/Q4 2023, including Phase 2 efficacy data for CYB003 and Phase 1 data for CYB004 - - U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2a data for end of Phase 2 meeting expected in Q4 2023 - - P...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, has closed its previously announced overnight marketed public offering. In connection with the...

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce tha...